Sugi Predict

Sugi Predict / Targets / GALK1

GALK1

Galactokinase · P51570 · GALK1 on Sugi Atlas →

19,308 patent compounds predicted against GALK1, 13,236 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL880379 SCHEMBL880379 0.52 8/20
SCHEMBL212616 SCHEMBL212616 0.37 6/20
SCHEMBL687001 SCHEMBL687001 0.65 4/20
SCHEMBL687453 SCHEMBL687453 0.65 4/20
SCHEMBL686569 SCHEMBL686569 0.53 4/20
SCHEMBL686944 SCHEMBL686944 0.51 4/20
SCHEMBL686945 SCHEMBL686945 0.51 4/20
9,10-Phenanthrenequinone 9,10-Phenanthrenequinone (SCHEMBL43050) 1.00 3/20
SCHEMBL432206 SCHEMBL432206 0.87 3/20
SCHEMBL1143226 SCHEMBL1143226 0.83 3/20
SCHEMBL717489 SCHEMBL717489 0.66 3/20
SCHEMBL43327 SCHEMBL43327 0.63 3/20
SCHEMBL433552 SCHEMBL433552 0.61 3/20
SCHEMBL745377 SCHEMBL745377 0.59 3/20
2-Chloro-3-Morpholino-1,4-Naphthoquinone 2-Chloro-3-Morpholino-1,4-Naphthoquinone (SCHEMBL197256) 0.58 3/20
SCHEMBL347152 SCHEMBL347152 0.57 3/20
SCHEMBL1055754 SCHEMBL1055754 0.54 3/20
SCHEMBL563010 SCHEMBL563010 0.52 3/20
SCHEMBL1234836 SCHEMBL1234836 0.45 3/20
SCHEMBL687515 SCHEMBL687515 0.41 3/20

Clinical trials — most relevant to GALK1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
A Double-Blind, Placebo-Controlled Study of Fermented Deglycyrrhizinated Licorice Extract PHASE2COMPLETED
A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy PHASE2COMPLETED
A Multi-center 12-week Study of HMS5552 in T2DM PHASE2COMPLETED
The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride PHASE1COMPLETED
Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus PHASE1COMPLETED
Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function PHASE1COMPLETED
Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection PHASE1COMPLETED
PET/CT to Image Hypoxia in Head and Neck Tumours EARLY_PHASE1COMPLETED
Dried Fruit and Postprandial Glycemia Trial nanUNKNOWN
Glycosylation in Patients With Galactosaemia nanCOMPLETED
Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption nanUNKNOWN
The GALAXY-1 Project nanUNKNOWN
Galactose Mediated Glycogen Resynthesis nanCOMPLETED
Dietary Treatment Strategies and Metabolic Control in Glycogen Storage Disease Type I nanRECRUITING
Effect of Acute Fructose Load in Human nanCOMPLETED
The Role of Sugars in Fat Accumulation in the Liver nanRECRUITING
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease nanRECRUITING
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation nanCOMPLETED
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease nanRECRUITING
Evaluation of Blood Protein O-GlcNAcylation Levels in Children nanRECRUITING
Genetic-specific Effects of Fructose on Liver Lipogenesis nanCOMPLETED
Evaluation of Blood and Cardiac Protein O-GlcNAcylation Levels in Cardiac Surgery in Children nanRECRUITING
Effect of Low Dose Galactose on Glycaemia and Glucose Kinetics nanRECRUITING
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Effects of Polyphenols Found in Pomegranate and Olives Food Supplements on Postprandial Blood Glucose in Vivo. nanCOMPLETED
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy nanUNKNOWN
Effects of Dual-Source Carbohydrate Intake and Liver Glycogen Repletion After Overnight Fasting. nanNOT_YET_RECRUITING
Effect of Migalastat on Cardiac Involvement in Fabry Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GALK1 binder may also engage these)

ProteinNameSimilarity
Q9GKK4 — 1.000 Q9GKK4 →
Q9R0N0 — 0.993 Q9R0N0 →
A6H768 — 0.992 A6H768 →
B9LFE4 — 0.983 B9LFE4 →
Q2JQU4 — 0.982 Q2JQU4 →
A9WB97 — 0.981 A9WB97 →
Q2JXY2 — 0.981 Q2JXY2 →
Q3AYC9 — 0.980 Q3AYC9 →
Q7NHM2 — 0.980 Q7NHM2 →
B7M1U1 — 0.979 B7M1U1 →
Q87TT8 — 0.979 Q87TT8 →
B1IP76 — 0.979 B1IP76 →
B8HVK5 — 0.979 B8HVK5 →
B7MPP1 — 0.979 B7MPP1 →
B7M6C0 — 0.979 B7M6C0 →
Q0TC78 — 0.979 Q0TC78 →
Q65UV5 — 0.979 Q65UV5 →
B1LM48 — 0.978 B1LM48 →
B7MGL4 — 0.978 B7MGL4 →
Q2JQB4 — 0.978 Q2JQB4 →
A1TP41 — 0.978 A1TP41 →
A5GWH4 — 0.978 A5GWH4 →
A4VHG9 — 0.978 A4VHG9 →
Q7NLJ6 — 0.978 Q7NLJ6 →
B8GCS2 — 0.978 B8GCS2 →
Q8DI27 — 0.977 Q8DI27 →
B0RXI2 — 0.977 B0RXI2 →
Q2JLP6 — 0.977 Q2JLP6 →
A4WFH7 — 0.977 A4WFH7 →
Q9RXF1 — 0.977 Q9RXF1 →